{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:09:25Z","timestamp":1789495765775,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"DOI":"10.1038\/s41391-026-01089-5","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:39:21Z","timestamp":1771673961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modern day cost analysis demonstrates medical therapy as a highly cost\u2011effective first\u2011line treatment for BPH\/LUTS"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-7196","authenticated-orcid":false,"given":"Alexis E.","family":"Te","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-7306","authenticated-orcid":false,"given":"Steven A.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"1089_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3949\/ccjm.91a.23027","volume":"91","author":"ES Haile","year":"2024","unstructured":"Haile ES, Sotimehin AE, Gill BC. Medical management of benign prostatic hyperplasia. Cleve Clin J Med. 2024;91:163\u201370. https:\/\/doi.org\/10.3949\/ccjm.91a.23027.","journal-title":"Cleve Clin J Med"},{"key":"1089_CR2","unstructured":"Impax Laboratories, Inc. Impax Laboratories receives final FDA approval for generic Flomax 0.4 mg capsules and immediately commences shipment [press release]. 2010."},{"key":"1089_CR3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1097\/JU.0000000000003698","volume":"210","author":"JS Sandhu","year":"2023","unstructured":"Sandhu JS, Bixler BR, Dahm P, Das AK, Gandhi MC, Kaplan SA, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2023;210:1116\u201326. https:\/\/doi.org\/10.1097\/JU.0000000000003698.","journal-title":"J Urol"},{"key":"1089_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","volume":"84","author":"S Gravas","year":"2023","unstructured":"Gravas S, Gacci M, Gratzke C, Herrmann T, Karavitakis M, Kyriazis I, et al. Summary of the 2023 European Association of Urology Guidelines on the Management of Male Lower Urinary Tract Symptoms. Eur Urol. 2023;84:207\u201322. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.008.","journal-title":"Eur Urol"},{"key":"1089_CR5","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista O, Andriole GL Jr, Dixon CM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med. 2003;349:2387\u201398. https:\/\/doi.org\/10.1056\/NEJMoa030656.","journal-title":"N Engl J Med"},{"key":"1089_CR6","doi-asserted-by":"publisher","first-page":"E682","DOI":"10.5489\/cuaj.1893","volume":"7","author":"S Isharwal","year":"2013","unstructured":"Isharwal S, Johanning JM, Dwyer JG, Schiffman MH, Berger PB. Cost-effectiveness of fixed-dose combination of dutasteride and tamsulosin (Duodart) compared with dutasteride monotherapy in patients with benign prostatic hyperplasia: a Canadian perspective. Can Urol Assoc J. 2013;7:E682\u201390. https:\/\/doi.org\/10.5489\/cuaj.1893.","journal-title":"Can Urol Assoc J"},{"key":"1089_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG, Siami P, Barkin J, Dami\u00e3o R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year results from the CombAT study. Eur Urol. 2010;57:123\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2009.09.035.","journal-title":"Eur Urol"},{"key":"1089_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1464-410X.2011.10521.x","volume":"109","author":"TE Bjerklund Johansen","year":"2012","unstructured":"Bjerklund Johansen TE, Baker TM, Black LK. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the CombAT trial. BJU Int. 2012;109:731\u20138. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10521.x.","journal-title":"BJU Int"},{"key":"1089_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61977-5","volume":"14","author":"BT Yoosuf","year":"2024","unstructured":"Yoosuf BT, Panda A, Bharti MK, Devana SK, Bansal SK. D. Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Sci Rep. 2024;14:11116. https:\/\/doi.org\/10.1038\/s41598-024-61977-5.","journal-title":"Sci Rep"},{"key":"1089_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/UPJ.0000000000000229","volume":"8","author":"G Eure","year":"2021","unstructured":"Eure G, Rukstalis D, Lee R, Concepcion RS, Ukani M. Cost-effectiveness comparison of prostatic urethral lift versus medical management and transurethral resection of the prostate for moderate-to-severe BPH. Urol Pract. 2021;8:487\u201392. https:\/\/doi.org\/10.1097\/UPJ.0000000000000229.","journal-title":"Urol Pract"},{"key":"1089_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/JU.0000000000001778","volume":"206","author":"KT McVary","year":"2021","unstructured":"McVary KT, Roehrborn CG. Five-year results of the prospective, randomized controlled trial of water vapor thermal therapy for BPH. J Urol. 2021;206:715\u201324. https:\/\/doi.org\/10.1097\/JU.0000000000001778.","journal-title":"J Urol"},{"key":"1089_CR12","first-page":"8802","volume":"24","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five-year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24:8802\u201313.","journal-title":"Can J Urol"},{"key":"1089_CR13","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1007\/s00270-017-1700-7","volume":"40","author":"S Bagla","year":"2017","unstructured":"Bagla S, Smirniotopoulos J, Orlando JC, Piechowiak R. Cost analysis of prostate artery embolization (PAE) and transurethral resection of the prostate (TURP) in the treatment of benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2017;40:1694\u20137. https:\/\/doi.org\/10.1007\/s00270-017-1700-7.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1089_CR14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/bju.14667","volume":"123","author":"G M\u00fcllhaupt","year":"2019","unstructured":"M\u00fcllhaupt G, Hechelhammer L, Engeler DS, Gusewell S, Mordasini L, Schmid HP, Abt D. In-hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial. BJU Int. 2019;123:1055\u201360. https:\/\/doi.org\/10.1111\/bju.14667.","journal-title":"BJU Int"},{"key":"1089_CR15","doi-asserted-by":"publisher","first-page":"e000071","DOI":"10.1136\/bmjsit-2020-000071","volume":"3","author":"S Modi","year":"2021","unstructured":"Modi S, Ahmed K, Abboudi H, Vigneswaran G, de Preux L, Maclean D, et al. One-year cost-utility analysis of prostate artery embolization versus transurethral resection of the prostate in benign prostatic hyperplasia. BMJ Surg Interv Health Technol. 2021;3:e000071. https:\/\/doi.org\/10.1136\/bmjsit-2020-000071.","journal-title":"BMJ Surg Interv Health Technol"},{"key":"1089_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100672","volume":"31","author":"M Sapoval","year":"2023","unstructured":"Sapoval M, Thiounn N, Descazeaud A, D\u00e9an C, Ruffion A, de la Taille A, et al. Prostatic artery embolisation versus medical treatment in patients with BPH (PARTEM): a randomised, multicentre, open-label phase 3 trial. Lancet Reg Health Eur. 2023;31:100672. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100672.","journal-title":"Lancet Reg Health Eur"},{"key":"1089_CR17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/03007995.2022.2057155","volume":"38","author":"KM Johnston","year":"2022","unstructured":"Johnston KM, Gupte-Singh K, Erickson K, Mason-Lai P, McVary KT. A cost-effectiveness analysis evaluating water vapor thermal therapy for benign prostatic hyperplasia. Curr Med Res Opin. 2022;38:1089\u201397. https:\/\/doi.org\/10.1080\/03007995.2022.2057155.","journal-title":"Curr Med Res Opin"},{"key":"1089_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41391-023-00741-8","volume":"27","author":"RP Kaufman Jr","year":"2024","unstructured":"Kaufman RP Jr, Bagley DH, Krane RJ, Whitmore KE, Kogan BA, Hanno PM, et al. Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study. Prostate Cancer Prostatic Dis. 2024;27:138\u201347. https:\/\/doi.org\/10.1038\/s41391-023-00741-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1089_CR19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00270-022-03199-8","volume":"45","author":"T Bilhim","year":"2022","unstructured":"Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E, Pisco JM, et al. Long-term outcome of prostatic artery embolization for patients with BPH: single-centre retrospective study in 1072 patients over a 10-year period. Cardiovasc Intervent Radiol. 2022;45:1324\u201336. https:\/\/doi.org\/10.1007\/s00270-022-03199-8.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1089_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2021.02.008","volume":"80","author":"D Abt","year":"2021","unstructured":"Abt D, Hechelhammer L, M\u00fcllhaupt G, Markart S, G\u00fcsewell S, Schmid HP, et al. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-year outcomes of a randomized, open-label, single-centre trial. Eur Urol. 2021;80:34\u201342. https:\/\/doi.org\/10.1016\/j.eururo.2021.02.008.","journal-title":"Eur Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01089-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01089-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01089-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:39:22Z","timestamp":1771673962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01089-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":20,"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01089-5","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with relevant guidelines and regulations. This article is a narrative review and analysis of published literature and publicly available information and did not involve new studies of human participants or animals; therefore approval from an ethics committee and informed consent to participate were not required. No identifiable human images are included; consent for publication was not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}